Skip to main content

Nayzilam Side Effects

Generic name: midazolam

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jan 17, 2024.

Note: This document contains side effect information about midazolam. Some dosage forms listed on this page may not apply to the brand name Nayzilam.

Applies to midazolam: injection solution. Other dosage forms:


Injection route (Solution)

Midazolam has been associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings. Use only in settings that can provide for continuous monitoring of respiratory and cardiac function. The initial dose and all subsequent doses should always be titrated slowly. Midazolam injection should not be administered by rapid injection in the neonatal population as severe hypotension and seizures have been reported.

Serious side effects of Nayzilam

Along with its needed effects, midazolam (the active ingredient contained in Nayzilam) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking midazolam:

Less common

Get emergency help immediately if any of the following symptoms of overdose occur while taking midazolam:

Symptoms of overdose

Other side effects of Nayzilam

Some side effects of midazolam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common


For Healthcare Professionals

Applies to midazolam: compounding powder, injectable solution, intramuscular solution, intravenous solution, nasal spray, oral syrup.


The most commonly reported side effects with oral formulations include emesis and nausea. Decreased tidal volume/respiratory rate and apnea were most commonly reported with parenteral formulations.[Ref]



Very common (10% or more): Respiratory adverse events (up to 11%)

Common (1% to 10%): Respiratory depression, hypoxia, laryngospasm, upper airway obstruction, rhonchi, congestion

Uncommon (0.1% to 1%): Sneezing/rhinorrhea

Frequency not reported: Apnea, hypercarbia, desaturation, stridor, hiccough


Very common (10% or more): Decreased tidal volume/respiratory rate (up to 23.3%), apnea (up to 15.4%)

Common (1% to 10%): Hiccoughs, coughing, desaturation

Very rare (less than 0.01%): Dyspnea, hiccup, laryngospasm, respiratory arrest

Frequency not reported: Respiratory depression

Postmarketing reports: Bronchospasm, hyperventilation, wheezing, shallow respirations, airway obstruction, tachypnea, dysphonia, yawning, continued phonation[Ref]

Respiratory adverse events included hypoxia, laryngospasm, rhonchi, coughing, respiratory depression, airway obstruction, upper airway congestion, and shallow respirations; these side effects occurred more frequently at higher doses.

Decreased tidal volume/respiratory rate occurred in 23.3% of patients given IV formulations and in 10.8% of patients given IM formulations.

Apnea occurred in 15.4% of patients given IV formulations.[Ref]



Very common (10% or more): Emesis/vomiting (up to 11%)

Common (1% to 10%): Nausea

Frequency not reported: Gagging, salivation


Common (1% to 10%): Nausea, vomiting

Very rare (less than 0.01%): Constipation, dry mouth

Postmarketing reports: Acid taste, excessive salivation, retching, toothache[Ref]

Nervous system


Common (1% to 10%): Sedation/prolonged sedation, somnolence, depressed levels of consciousness

Frequency not reported: Drooling, dizziness, ataxia, vertigo, dysarthria, loss of balance


Common (1% to 10%): Headache, oversedation, drowsiness, seizure-like activity

Very rare (less than 0.01%): Movement disorder, ataxia, dizziness, seizure, anterograde amnesia

Frequency not reported: Involuntary movements, hyperactivity, decreased alertness, somnolence, prolonged/postoperative sedation, convulsions/drug withdrawal convulsions, feeling faint, tonic/clonic movements and muscle tremor

Postmarketing reports: Vasovagal episode, retrograde amnesia, grogginess, athetoid movements, lethargy, slurred speech, paresthesia, loss of balance, lightheadedness, feeling of burning, emergence delirium or agitation[Ref]



Common (1% to 10%): Bradycardia, bigeminy

Frequency not reported: Increased heart rate, cardiac arrest, heart failure, decreased systolic and diastolic blood pressure


Common (1% to 10%): Hypotension

Very rare (less than 0.01%): Bradycardia, cardiac arrest, vasodilation

Frequency not reported: Thrombophlebitis, thrombosis, variations in blood pressure and pulse rate

Postmarketing reports: Bigeminy, premature ventricular contractions, tachycardia, nodal rhythm, hematoma, cardiovascular collapse, cardiovascular reactions, severe cardiorespiratory adverse events[Ref]



Common (1% to 10%): IM injection site pain, IV site tenderness/pain during injection/redness/induration

Uncommon (0.1% to 1%): IM injection site induration/redness/muscle stiffness, IV site phlebitis

Frequency not reported: Injection site erythema, injection site pain

Postmarketing reports: Hive-like elevation at injection site, warmth or coldness at injection site[Ref]



Common (1% to 10%): Agitation

Frequency not reported: Dysphoria, disinhibition, excitation, aggression, mood swings, hallucinations, confusion, inappropriate/adverse behavior, behavioral/emotional disorders, euphonia, libido disorders, restlessness, irritability, delusions, anger eruptions, nightmares, psychosis, physical dependency, withdrawal symptoms, abuse, depression (existing, unobserved depression)


Very rare (less than 0.01%): Aggression/aggressiveness, agitation, anger, hallucination, hostility, confusion/confusional state, euphoric mood/euphoria

Frequency not reported: Rage, excitement/paroxysmal excitement, abuse, physical drug dependence and withdrawal syndrome

Postmarketing reports: Argumentativeness, nervousness, anxiety, restlessness, sleep disturbance, insomnia, nightmares, dysphoria, irritability, tension, mood changes, dreaming during sleep[Ref]



Common (1% to 10%): Rash

Uncommon (0.1% to 1%): Pruritus and urticaria


Frequency not reported: Angioedema

Postmarketing reports: Hives, rash, pruritus, skin reactions[Ref]



Frequency not reported: Diplopia, strabismus, blurred vision


Common (1% to 10%): Nystagmus

Postmarketing reports: Blurred vision, diplopia, pinpoint pupils, visual disturbance, difficulty focusing eyes, cyclic movement of the eyelids[Ref]



Frequency not reported: Fatigue, falls


Common (1% to 10%): Paradoxical reaction

Very rare (less than 0.01%): Fatigue, falls, assault/physical assault

Postmarketing reports: Prolonged emergence from anesthesia, blocked ears, chills, weakness, swelling, dreaming during emergence[Ref]



Frequency not reported: Hypersensitivity


Frequency not reported: Hypersensitivity, anaphylactic shock

Postmarketing reports: Allergic reaction, anaphylactoid reactions[Ref]



Frequency not reported: Muscle weakness, fractures


Frequency not reported: Fractures[Ref]

Frequently asked questions


1. Product Information. Versed (midazolam). Roche Laboratories. 2001;PROD.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.